The first volunteer to receive an experimental Ebola vaccine
The article reports on a new experimental Ebola vaccine trial, highlighting that the first volunteer has received the dose developed by researchers at Oxford University. The vaccine targets the Bundibugyo strain, which caused an outbreak in the Democratic Republic of Congo (DRC) and Uganda, resulting in over 1,000 deaths. The vaccine was developed in eight weeks using technology similar to the Oxford-AstraZeneca COVID-19 vaccine. Researchers emphasize that the rapid development was due to prior decades of research rather than shortcuts. The trial involves 50 volunteers, including the 37-year-old British participant Ed Hunt, who expressed willingness to contribute to combating the deadly outbreak. The vaccine does not contain live Ebola virus and cannot cause infection. It is being funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with the Indian Serum Institute producing 620,000 doses. The World Health Organization (WHO) reports nearly 3,000 infections and over 1,270 deaths from the current outbreak, which is the 17th in DRC’s history and the third involving the Bundibugyo strain. The WHO warns that the outbreak is outpacing health services, particularly in hard
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and your personalized For You feed.
The article reports on a new experimental Ebola vaccine trial, highlighting that the first volunteer has received the dose developed by researchers at Oxford University. The vaccine targets the Bundibugyo strain, which caused an outbreak in the Democratic Republic of Congo (DRC) and Uganda, resulting in over 1,000 deaths. The vaccine was developed in eight weeks using technology similar to the Oxford-AstraZeneca COVID-19 vaccine. Researchers emphasize that the rapid development was due to prior decades of research rather than shortcuts. The trial involves 50 volunteers, including the 37-year-old British participant Ed Hunt, who expressed willingness to contribute to combating the deadly outbreak. The vaccine does not contain live Ebola virus and cannot cause infection. It is being funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with the Indian Serum Institute producing 620,000 doses. The World Health Organization (WHO) reports nearly 3,000 infections and over 1,270 deaths from the current outbreak, which is the 17th in DRC’s history and the third involving the Bundibugyo strain. The WHO warns that the outbreak is outpacing health services, particularly in hard
Bias read (Center): The article presents a balanced report on scientific developments related to an Ebola vaccine, focusing on medical and public health aspects without overtly promoting any political agenda. While the topic relates to global health crises and international cooperation, the framing remains neutral, and
A volunteer received the first dose of a new experimental vaccine against the Ebola virus strain Bundibugyo, which has caused a deadly outbreak in the Democratic Republic of Congo (DRC) and Uganda. The vaccine, developed by researchers at the University of Oxford in eight weeks using technology similar to the Oxford-AstraZeneca COVID-19 vaccine, was administered to a British man named Ed Hunt. The trial aims to assess the vaccine’s safety and whether it triggers a strong enough immune response to protect against the virus. The vaccine does not contain live Ebola virus and cannot cause infection. Researchers note that while there is already an approved vaccine for the Zaire Ebola strain, no vaccine exists yet for Bundibugyo. The outbreak has resulted in over 3,000 infections and more than 1,270 deaths, according to the World Health Organization (WHO). WHO director-general Tedros Adhanom Ghebreyesus warned that the outbreak is outpacing the response of health services due to challenges in reaching remote areas and ongoing conflicts.
Bias read (Center): The article provides balanced information about the development of a new Ebola vaccine, including quotes from both the volunteer and researchers, mentions the scale of the outbreak, and references the World Health Organization. There is no evident ideological framing or biased language.
The first volunteer has received a trial dose of a new experimental vaccine against the Bundibugyo ebola virus, which causes deadly outbreaks in the Democratic Republic of Congo (DRC). The vaccine, called ChAdOx1 BDBV, was developed by researchers at the University of Oxford in eight weeks using technology similar to that used in the Oxford-AstraZeneca coronavirus vaccine. The trial involves 50 healthy volunteers, including 37-year-old British participant Ed Hunt, who expressed his desire to contribute to saving lives. Researchers emphasized that the rapid development was due to decades of prior research rather than shortcuts. The vaccine does not contain live Ebola virus and cannot cause infection. It is being tested for safety and immune response in the first phase of clinical trials. Development is funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with the Indian Serum Institute producing 620,000 doses. The outbreak in DRC and Uganda has caused over 1,200 deaths, with the World Health Organization (WHO) warning that the outbreak still outpaces health services' response due to limited access in remote areas. No approved vaccine exists for the Bundibugyo strain
Bias read (Center): The article presents factual information about a medical trial and public health issue without overt ideological slant. While the topic relates to global health policy and international cooperation, the framing remains neutral, focusing on scientific progress and humanitarian efforts without taking,
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Slovenia
